# Immune-Onc Therapeutics: Research, Palo Alto, United States

> Immune-Onc Therapeutics: Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California.

Source: https://millionrounds.com/startup/immune-onc-therapeutics (Millionrounds; every figure on the page links to its filing or article)

United States · [Research startup](https://millionrounds.com/companies)

# Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California.

Email

Funding reported Last round: Series B

Research Palo Alto, United States

Follow Immune-Onc Therapeutics and see its new rounds in your feed. [Start following](https://millionrounds.com/login?join=1&why=follow&next=%2Fstartup%2Fimmune-onc-therapeutics)

Company summary

- **Founded:** 2016 10 years old
- **Team:** 12 11 to 50 people
- **Funding reported:** $140M in dollars
- **Last round:** Series B Jan 2023

How sure we are

- ✓ **Listed** We know it exists and what it does
- 2 **Funding reported** A company dataset reports a raise
- 3 **Observed** A filing or a dated announcement confirms a round

No round for Immune-Onc Therapeutics has been confirmed by a filing or an announcement yet, so nothing here counts toward an investor's record. [How we decide](https://millionrounds.com/methodology)

## About Immune-Onc Therapeutics

Immune-Onc Therapeutics is a clinical-stage biopharmaceutical company based in Palo Alto, California.

Founded in September 2016 by Charlene Liao, the company focuses on developing innovative biotherapeutics that target myeloid cell inhibitory receptors. Their mission is to enhance the lives of patients with challenging cancers and autoimmune diseases through the creation of novel myeloid checkpoint inhibitors. The company has a dedicated team of 18 to 24 employees and has successfully raised $138 million in funding, including a significant $73 million in Series B1 and B2 financing in March 2021. Immune-Onc is advancing a pipeline of drug candidates, including IO-202 for acute myeloid leukemia and IO-108 for solid tumors and hematologic malignancies. Their approach aims to disarm immune suppression in the tumor microenvironment, allowing the immune system to effectively target cancer cells. Immune-Onc collaborates with scientists, academic institutions, and non-profit organizations to further their research and development efforts.

## What company datasets say Immune-Onc Therapeutics raised

Funding, as reported

Reported in all **$140M** in dollars

Rounds **6**

Last round **Series B**

Last round size **$25M**

Last round date **Jan 2023**

Investors listed **6**

SEC Form D **$7.0M sold, 1 filing, last Sept 2016**

## Founders and team

From the SEC filings it signed: 2 on the team.

- **Guo-Liang Yu** Board of Directors
- **Xiaoling Charlene Liao** Executive Officer, Director i

On the board, as filed i *Liqun Luo*

## On 2 portfolio pages

Investors who name them

- [Vivo Capital](https://millionrounds.com/fund/vivo-capital)
- [CLI Ventures](https://millionrounds.com/fund/cli-ventures)

Each firm lists Immune-Onc Therapeutics on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

## The company, in detail

What they build

Known for

health care bispecific antibody platform monoclonal antibodies immune regulation research grants biotechnology research myeloid cell modulation blood cancers targeted antibodies lair1 targeting clinical-stage biopharmaceutical hematologic malignancies immune-onc therapeutics immune checkpoint targets immunology and oncology therapies autoimmune disease therapy

Built with from their website

Adobe parallax.js Squarespace ECommerce CloudFlare Viewport Meta Google Drive Element UI Adobe Experience Manager Apple Business Manager Priority Hints

+8 more

Magento 2 Microsoft Exchange Microsoft 365 Apps & Services Mobile Friendly Magento Open Source Open Graph jQuery RSS

- **Sector:** Research
- **Industry code:** NAICS 541714, SIC 2834
- **Region:** California
- **Revenue:** $5.0M a year, as listed

## Research in United States

Startups like it

- [**OpenAI** San Francisco · founded 2011 *Raised*](https://millionrounds.com/company/openai)
- [**Retro Biosciences** Redwood City · founded 2021 *Raised*](https://millionrounds.com/company/retro-biosciences)
- [**NewLimit** South San Francisco · founded 2022 *Raised*](https://millionrounds.com/company/newlimit)
- [**Pathos** New York · founded 2022 *Raised*](https://millionrounds.com/company/pathos)
- [**Colossal Biosciences** Dallas · founded 2021 *Raised*](https://millionrounds.com/company/colossal-biosciences)
- [**Oratomic** South Pasadena *Raised*](https://millionrounds.com/company/oratomic)
- [**Beeline Medicines** Stamford · founded 2025 *Raised*](https://millionrounds.com/company/beeline-medicines)
- [**Element Biosciences** San Diego · founded 2017 *Raised*](https://millionrounds.com/company/element-biosciences)

## Is this your company?

Add your raise, your deck and your story, and put Immune-Onc Therapeutics in front of investors. Or tell us what we have wrong.

[List your startup](https://millionrounds.com/list-your-startup)[Send a correction](https://millionrounds.com/corrections)